SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 34.42 |
| Enterprise Value ($M) | 17.72 |
| Book Value ($M) | 14.07 |
| Book Value / Share | 0.79 |
| Price / Book | 2.45 |
| NCAV ($M) | 12.98 |
| NCAV / Share | 0.73 |
| Price / NCAV | 2.65 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.44 |
| Return on Assets (ROA) | -1.19 |
| Return on Equity (ROE) | -3.41 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.95 |
| Current Ratio | 2.95 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 20.15 |
| Assets | 21.24 |
| Liabilities | 7.17 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -32.18 |
| Net Income | -32.12 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -27.95 |
| Cash from Investing | 14.53 |
| Cash from Financing | 17.80 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | 3i, LP | 7.60 | ||
| 13D/A | Acuitas Group Holdings, LLC | 44.53 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 130,817 | 333,254 | 39.25 | |
| 203,614 | 624,600 | 32.60 | |
| 256,725 | 594,635 | 43.17 | |
| 477,846 | 1,462,801 | 32.67 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BFRG – Bullfrog AI Holdings, Inc. | BFRI – Biofrontera Inc. |
| BGM – BGM Group Ltd. | BMRA – Biomerica, Inc. |
| BNTC – Benitec Biopharma Inc. |
Financial data and stock pages provided by
Fintel.io